Search Within

Shanu Modi

Formats
  1. Meeting Abstract (150)
  2. Journal Article (99)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (265)
  2. Department of Medicine (265)
  3. Solid Tumor Oncology Division (265)
  4. Survivorship Research (113)
  5. GSK Faculty (104)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (88)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (49)
  4. Sujata Patil (44)
  5. Chau Dang (41)
  6. Komal Jhaveri (34)

More People

Years
  1. 2025 (5)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (265)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Burris, H. A.; Krop, I. E.; Modi, S.; Rodon, J.; Lutzker, S. G.; Holden, S. N.; Bhattacharya, S.; Sliwkowski, M.; Beeram, M.
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • A phase I study of cetuximab in combination with paclitaxel in patients with advanced-stage breast cancer
    Journal Article

    Modi, S.; D'Andrea, G.; Norton, L.; Yao, T. J.; Caravelli, J.; Rosen, P. P.; Hudis, C.; Seidman, A. D.
    Clinical Breast Cancer (2006)

    Fulltext@MSK | Save
  • Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
    Meeting Abstract

    Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.; Dickler, M.; Moasser, M.; D'Andrea, G.; Moynahan, M. E.; Menell, J.; Panageas, K. S.; Tan, L. K.; Norton, L.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Combination versus sequential single-agent therapy for the treatment of metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A.
    EJC Supplements (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Journal Article

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Cancer Investigation (2005)

    Fulltext@MSK | Save
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save
  • Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Journal Article

    Fornier, M. N.; Modi, S.; Panageas, K. S.; Norton, L.; Hudis, C.
    Cancer (2005)

    Fulltext@MSK | Save
  • Single-agent gemcitabine in the treatment of advanced breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.
    Clinical Breast Cancer (2004)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for meta-static breast cancer (MBC)
    Meeting Abstract

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Proceedings of the American Association for Cancer Research Annual Meeting (2003)

    Fulltext@MSK | Save